Anti-VEGFs boost outcomes in patients with DME

03/12/2013 |

Anti-vascular endothelial growth factor-A medications such as ranibizumab and bevacizumab were associated with significant short-term improvements and few adverse effects in patients with diabetic macular edema, an analysis in BMJ Open indicated. Researchers said anti-VEGFs may offer more consistent results compared with laser and steroid therapies.

View Full Article in:

Published in Briefs:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Site Quality Management
Minneapolis, MN
Clinical Project Manager
Abiomed, Inc.
Danvers, MA
Sr. Manager, Regulatory Affairs - International
Integra LifeSciences
Plainsboro, NJ
Associate - Food and Drug
Keller and Heckman LLP
Washington, DC
In house Compliance Officer
Pompano Beach, FL